Biocon Ltd
05 Nov 2026 12:00 AM
Biocon Ltd consolidated sales up 1.24% on year in Q3FY2026,
Biocon Ltd share price gained 0.19% to Rs 344.0 after the company`s net profit tumbled by 58.55% to Rs 56.7 crore, while revenue from operations improved marginally 1.24% to Rs 4345.0 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, rising 5.14%. It has marginally improved by 2.03% over last one week and moved up slightly by 1.77% in last one month while the market capitalization of Biocon Ltd has slipped by 2.27% and 20% in the same period respectively.
Profit before tax (PBT) of Biocon Ltd stood at Rs 54.8 crore in Q3 FY26, nosediving by 68.01% year-on-year, and tumbling by 57.05% quarter-on-quarter. EBITDA came in at Rs 796 crore, gaining 7.27% YoY and easing 0.47% sequentially.
Total expenses posted a minor rise of 2.12% to Rs 4121.8 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1669.0 crore, going up by 17.20% YoY, while employee benefits expense was at Rs 891.9 crore, slipping by 3.90% YoY.
For the TTM ended FY26, revenue from operations rose 11.48% to Rs 16779.9 crore, while net profit witnessed a sharp fall of 74.20% to Rs 368.8 crore, compared to previous TTM. EBITDA soared by 222680% to Rs 3112.8 crore, and PBT tanked by 76.26% to Rs 447.9 crore compared to previous TTM.
The company`s consolidated net cash flow from operating activities stood at Rs 1994.0 crore in FY26, as against Rs 4061.2 crore in FY25.
Biocon Ltd nosedived by 9.53% in last one year, significantly underperforming the benchmark BSE Sensex which has softened by 7.38% during the same period.
Biocon Ltd
04 Nov 2026 12:00 AM
Biocon Ltd consolidated sales up 1.24% on year in Q3FY2026,
Biocon Ltd share price softened by 2.97% to Rs 343.35 after the company`s net profit plunged by 58.55% to Rs 56.7 crore, while revenue from operations slightly gained 1.24% to Rs 4345.0 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, easing 4.49%. It has inched up 1.84% over last one week and moved up slightly by 1.37% in last one month while the market capitalization of Biocon Ltd has eased by 1.90% and 21.52% in the same period respectively.
Profit before tax (PBT) of Biocon Ltd stood at Rs 54.8 crore in Q3 FY26, tanking 68.01% year-on-year, and plunging by 57.05% quarter-on-quarter. EBITDA came in at Rs 796 crore, gaining 7.27% YoY and rising 0.47% sequentially.
Total expenses posted a minor rise of 2.12% to Rs 4121.8 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1669.0 crore, going up by 17.20% YoY, while employee benefits expense was at Rs 891.9 crore, registering a marginal contraction of 3.90% YoY.
For the TTM ended FY26, revenue from operations improved 11.48% to Rs 16779.9 crore, while net profit tumbled by 74.20% to Rs 368.8 crore, compared to previous TTM. EBITDA jumped by 222680% to Rs 3112.8 crore, and PBT tanked by 76.26% to Rs 447.9 crore compared to previous TTM.
The company`s consolidated net cash flow from operating activities stood at Rs 1994.0 crore in FY26, as against Rs 4061.2 crore in FY25.
Biocon Ltd crashed 8.97% in last one year, performing in line with the benchmark BSE Sensex which has eased by 8.41% during the same period.
Biocon Ltd
06 Aug 2026 12:00 AM
Biocon consolidated net profit rises 349.36% in the June 2026 quarter,
Net profit of Biocon rose 349.36% to Rs 141.10 crore in the quarter ended June 2026 as against Rs 31.40 crore during the previous quarter ended June 2025. Sales rose 9.76% to Rs 4291.80 crore in the quarter ended June 2026 as against Rs 3910.10 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales4291.803910.10 10 OPM %19.7419.59 - PBDT688.50569.10 21 PBT141.10114.10 24 NP141.1031.40 349 Powered by Capital Market - Live News
Biocon Ltd
03 Aug 2026 12:00 AM
Biocon launches Yesafili¿ in U.S. market,
Biocon announced the commercial launch of Yesafili� (aflibercept-jbvf) in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA� (aflibercept) 2 mg. The product was approved previously and granted interchangeable designation* by the U.S. Food and Drug Administration in May 2024, allowing substitution at the pharmacy level in accordance with state laws. Shreehas Tambe, CEO & Managing Director, Biocon Ltd., said, �The launch of Yesafili�️ in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea�️ 2 mg, advancing access to life-changing medicines for patients around the world.�
Biocon Ltd
29 Jul 2026 12:00 AM
Biocon announces board meeting date,
Biocon will hold a meeting of the Board of Directors of the Company on 5 August 2026.
Subscribe for our
newsletter
newsletter
HSL Mobile App